Gene editing technology is used to insert, modify, or delete a gene from an organism’s genome and shows promise in the treatment of medical conditions ranging from cancer to rare genetic diseases. Our indicative theme on has returned over 170% since late 2018, compared to the larger S&P 500 which is up around 54% over the same period. The theme has returned around 2.4% since the start of the year. Investor interest in gene editing remains high, given the sector’s upside and considering that absolute valuations are not too high with most stocks remaining in the mid-cap space. has been the best performance in our theme this year so far, up 18% since early January. The gains come as the company has set its strategic priorities for 2021, including the continued advancement of a Phase 1 study for a one-course treatment for protein folding disorder and the planned submission of a regulatory application. for the treatment of acute myeloid leukemia. On the other hand, is down about 13% year-to-date, after the company said it planned to raise additional capital, issuing around 3.5 million shares at $ 66. per share. Check out our update below for a detailed look at the components of our theme. Gene editing has become a promising biotechnology topic. The technology is used to insert, modify or delete a gene from an organism’s genome, helping to replace defective genes responsible for a medical condition with healthy versions. This technology is used to develop treatments for a range of diseases from cancer to rare genetic diseases, which are otherwise difficult to treat, and is also being considered for diagnostic purposes. Although there are roughly three gene editing technologies, “regularly interspersed short palindromic repeats” or CRISPR, as it is commonly called, has become the method of choice for most companies, as it is relatively inexpensive, simpler and more flexible compared to other tools such as ZFN and TALEN. While most of the gene editing players remain in the clinical stage with limited financial histories, funding has increased significantly and large pharmaceutical companies are also partnering with these companies, as the treatments could be lucrative. and that broader technologies can be highly scalable. Although the increase remains significant, investing in these companies is risky. Being a new technology that has never been used in humans before, there are risks of significant side effects or that the therapies will not be effective. The profitability of the production and sale of these drugs also remains uncertain. These stocks are also volatile and experience large fluctuations as new research or data on their potential or risks is described. Our indicative theme on – which includes names like CRISPR Therapeutics, Editas Medicine, and others – has returned around 230% over the past 2 years, compared to the larger S&P 500 which is up around 52% on the same period. Below is a bit more information about these companies. is one of the most well-known names in the field of gene editing. The company is working with Vertex Pharmaceuticals to co-develop CTX001, an experimental gene therapy that has provided promising results for people with sickle cell disease and transfusion beta thalassemia – disorders that affect oxygen-carrying cells in human blood. The company is also independently developing cancer treatment candidates. The company was profitable last year, thanks to Vertex’s collaborative income.
- According to Forbes “Intellia, Editas: How are gene editing stocks doing?”.
Check all news and articles from the Money news and blog.